						ATTY. DOCKET NO.		APPLICA	ATION NO.	
					18528.632		10/656,093			
OE	OE C FORM PTO-1449				APPLICANTS					
6\r -	INF	<u> PRMATIO</u>	N DISCLOSURE	STATEMENT		Andrew A. YOUNG et al.				
	TIME !					FILING DATE		GROUP		
TEL 1		K OFFICE				September 5, 2003		To Be A	Assigned	
EXXM	.nev	7	•		U.\$.	PATENT DOCUMENTS		<u> </u>		
EXAM INITIA	NER		DOCUMENT NUMBER	DATE	NAME			CLASS	SUB-	SH DIC DATE
BL	<u> </u>	AAI	5,424,286	6/1995	Eng			CLASS	CLASS	FILING DATE
			5,512,549	4/1996	Chen					
		AB1	5,545,618	8/1996	Buckley				 	
$\vdash +$;	<u> </u>	
\vdash		AD1	5,574,008	11/1996	Johnson				 	
		AEI	5,846,937	12/1998	Drucker					<u> </u>
EXAM	DIED	T	DOCUMENT		FOREIC	ON PATENT DOCUMENTS			1	
INITIA			NUMBER	DATE	COUNTR	Y		CLASS	SUB- CLASS	TRANSLATION
		AFI	WO 98/05351	2/1998	PCT			-		Yes No
		AG1	WO 99/07404	2/1999	PCT					Yes No
		1	<u> </u>	OTHER	(Including	Author, Title, Date, Pertinent Pages,	etc.)		J	1
			Γ							
		AHI Barragán et al., "Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats", Regulatory Peptides, 67:63-68 (1996)								
		All	Bhavsar et al., "Inhibition of gastric emptying and of food intake appear to be independently controlled in rodents", Soc. Neurosci. Abstr., 21:460 (188.8) (1995)							
		D'Alessio et al., "Elimination of the Action of Glucagon-like Peptide 1 Causes an Impairment of Glucose Tolerance after Nutrient Ingestion by Healthy Baboons", J. Clin. Invest., 97(1):133-138 (1996)								
,	Edwards et al., "Cardiovascular and Pancreatic Endocrine Responses to Glucagon-Like Peptide-1(7-36) Amide in the Conscious Calf", Exp. Physiol., 82:709-716 (1997) AL1 Eissele et al., "Rat Gastric Somatostatin and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagon-Like Peptide-1 (GLP-1) Amide", Life Sci., 55(8):629-634 (1994)							(7-36) Amide in		
	Eng et al., "Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated from Heloderma horridum Venom", J. Biol. Chem., 265(33):20259-20262 (1990)							n Heloderma		
		ANI	Eng et al., "Is Venom", J. B	olation and o	Characteriz 267(11):740	eation of Exendin-4, an Exendir 02-7405 (1992)	n-3 Analo	gue, from	n Heloderm	a suspectum
\	V	A01	Characteristic 15(3):453-456	s Utilizing (5 (1994)		of the Rat GLP-1 Receptor in C 6)-Amide, Oxyntomodulin, Exe		nd Exendi	in(9-39)", <u>I</u>	Peptides,
EXAM	EXAMINER /Leon Lankford Jr/						DATE CO	NSIDERED 07/10/2	006	
EXAM consider	INER:	Initial if rel	ference considered of this form with ne	whether or no	ot citation is i	in conformance with MPEP 609. Dricant.	aw line thr	ough citatio	on if not in co	nformance and not

			ATTY, DOCKET NO.	APPLICATION NO.			
			18528.632	10/656,093			
			APPLICANTS	10/030,093			
YEK	RMATIO	FORM PTO-1449 N DISCLOSURE STATEMENT	Andrew A. YOUNG et al.				
J' F THE	ايس		FILING DATE GROUP				
2 72	€)		September 5, 2003	To Be Assigned			
dir	\$ /	OTHER (Industrial	<u> </u>				
TANT & TRAD	*	OTHER (Including	Author, Title, Date, Pertinent Pages, et	c.)			
BL	AA2	Ferguson et al., "Cell-Surface Anch Biochem., 57:285-320 (1988)	oring of Proteins via Glycosylpho	osphatidylinositol Structures", Annu. Rev.			
	Göke et al., "Exendin-4 is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting β-Cells", J. Biol. Chem., 268(26):19650-1965 (1993)						
	Knudsen et al., "Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for One Daily Administration", J. Med. Chem., 43:1664-1669 (2000)						
	AD2 Kolligs <i>et al.</i> , "Reduction of the Incretin Effect in Rats by the Glucagon-Like Peptide 1 Re Exendin (9-39) Amide", <u>Diabetes</u> , 44:16-19 (1995)						
	AE2	Malhotra et al., "Exendin-4, a new pamylase release from rat pancreatic	peptide from <i>Heloderma suspectu</i> acini", <u>Regulatory Peptides</u> , 41:1-	le from Heloderma suspectum venom, potentiates cholecystokinin-induced ', Regulatory Peptides, 41:149-156 (1992)			
	AF2	Montrose-Rafizadeh et al., "Structu 2):152A (1996)	re-function Analysis of Exendin-4	4 / GLP-1 Analogs", <u>Diabetes</u> , 45(Suppl.			
	AG2	O'Halloran et al., "Glucagon-like por Journal of Endocrinology, 126:169-		cal inhibitor of gastric acid secretion in man",			
	AH2	Ørskov et al., "Biological Effects ar Peptide-1 7-37 in Healthy Subjects	Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and Glucagonlike re Indistinguishable", <u>Diabetes</u> , 42:658-661 (1993)				
	A12	Raufman et al., "Exendin-3, a Nove Intestinal Peptide Receptors and a N Biol. Chem., 266(5):2897-2902 (199	lewly Described Receptor on Disp	um Venom, Interacts with Vasoactive persed Acini from Guinea Pig Pancreas", <u>J.</u>			
	AJ2	Raufman et al., "Truncated Glucago Guinea Pig Pancreas", J. Biol. Chen	agon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from hem., 267(30):21432-21437 (1992)				
	AK2 Schepp et al., "Exendin-4 and exendin-(9-39)NH ₂ : agonist and antagonist, re receptor for glucagon-like peptide-1-(7-36)NH ₂ ", <u>Eur. J. Pharm.</u> , 269:183-19						
	AL2	Schjoldager et al., "GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans", <u>Digestive Disease and Sciences</u> , 34(5):703-708 (1989)					
AM2 Singh et al., "Use of ¹²⁵ I-[Y ³⁹]exichief cells from guinea pig", Reg			endin-4 to characterize exendin receptors on dispersed pancreatic acini and gastric ulatory Peptides, 53:47-59 (1994)				
EXAMINER		/Leon Lankford Jr/		DATE CONSIDERED 07/10/2006			
EXAMINER: considered. Inc	Initial if re	ference considered, whether or not citation is of this form with next communication to App	in conformance with MPEP 609. Draw licant.	w line through citation if not in conformance and not			

			ATTY. DOCKET NO.	APPLICATION NO.			
			18528.632	10/656,093			
	_		APPLICANTS	10/030,033			
O ENEO		FORM PTO-1449 N DISCLOSURE STATEMENT	-				
611 - B	7		Andrew A. YOUNG et al. FILING DATE GROUP				
	<u> </u>						
HEE 1 2 ZULS	<u>됨</u>		September 5, 2003	To Be Assigned			
-	<u>8/</u>	OTHER (Including A	Author, Title, Date, Pertinent Pages, etc.)				
BL BL	AA3	Tang-Christensen et al., "Central adn Am. J. Physiol., 271:R848-R856 (199	Iministration of GLP-1-(7-36) amide inhibits food and water intake in rats", 996)				
	AB3	Thorens et al., "Expression cloning o peptide 1", Proc. Natl. Acad. Sci. US	of the Pancreatic β cell receptor for the gluco-incretin hormone glucagon-like SA, 88:8641-8645 (1992)				
	Thorens et al., "Cloning and Functional Expression of the Human Islet GLP-1 Receptor", <u>Diabetes</u> , 42:1678-(1993)						
	AD3 Turton et al., "A role for glucagon-like peptide-1 in the central regulation of feeding", Nature, 379:69-72 (1996						
	AE3	Wang et al., "Glucagon-like Peptide-	e-I is a Physiological Incretin in Rat", <u>J. Clin. Invest.</u> , 95:417-421 (1995)				
	AF3	Wettergren et al., "Truncated GLP-1 Man", Digestive Diseases and Science	(Proglucagon 78-107-Amide) Inhibits C es, 38(4):665-673 (1993)	Sastric and Pancreatic Functions in			
	AG3		ucose Responses, and Insulin Secretion (GLP-1)-(7-36) Amide in Type 2 (Non 7-332 (1996)				
	АН3	Young et al., "Preclinical Pharmacolo Drug Development Research, 37:231	ogy of Pramlintide in the Rat: Comparisons with Human and Rat Amylin", -248 (1996)				
\bigvee	AI3						
	AJ3						
	AK3						
	AL3						
	AM3						
EXAMINER		/Leon Lankford Jr/		DATE CONSIDERED 07/10/2006			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not							
considered. Include copy of this form with next communication to Applicant.							